Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study
Identifieur interne : 009056 ( Main/Exploration ); précédent : 009055; suivant : 009057Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study
Auteurs : Michèle Kessler [France] ; Faiez Zannad [France] ; Philippe Lehert [France] ; Jean Pierre Grünfeld [France] ; Christian Thuilliez [France] ; Alain Leizorovicz [France] ; Philippe Lechat [France]Source :
- Nephrology Dialysis Transplantation [ 0931-0509 ] ; 2007-12.
Abstract
Background. Cardiovascular events (CVE) are a major cause of morbidity and mortality in end-stage renal disease (ESRD) patients. These patients are often excluded from CV clinical trials, and the prognostic factors associated with CVE in patients with ESRD have not been fully explored. A risk prediction model was created from the FOSIDIAL trial to identify factors predictive of CVE and to evaluate the relative strength of known predictors when considered together in a multivariate model. Methods. FOSIDIAL was a prospective, randomized, double-blind study with 2-year follow-up and CVE adjudication. The study enrolled 397 patients with ESRD and left ventricular hypertrophy (LVH). CVE included cardiovascular death, non-fatal myocardial infarction, unstable angina, stroke, revascularization, heart failure hospitalization, resuscitated cardiac arrest and confirmed stroke. The model was built using a forward selection of all baseline variables. A structural equation model (SEM) was used to identify factors with an indirect association with CVE. Results. CV history was the most important prognostic factor, followed by C-reactive protein (CRP), left ventricular mass index, diabetes and age. Smoking, low HDL, female gender and Kt/V were indirectly associated with CVE. Conclusion. Prior CV disease, elevated CRP, LVH, diabetes or advanced age identifies patients at the highest risk for CVE. These data may be useful to detect high risk patients, to define potential targets for pharmacologic intervention, and to plan future studies in ESRD. Further research is needed to identify effective approaches that reduce the rate of CVE in these patients.
Url:
DOI: 10.1093/ndt/gfm417
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001721
- to stream Istex, to step Curation: 001721
- to stream Istex, to step Checkpoint: 001295
- to stream Main, to step Merge: 009A29
- to stream Main, to step Curation: 009056
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study</title><author><name sortKey="Kessler, Michele" sort="Kessler, Michele" uniqKey="Kessler M" first="Michèle" last="Kessler">Michèle Kessler</name></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name></author><author><name sortKey="Grunfeld, Jean Pierre" sort="Grunfeld, Jean Pierre" uniqKey="Grunfeld J" first="Jean Pierre" last="Grünfeld">Jean Pierre Grünfeld</name></author><author><name sortKey="Thuilliez, Christian" sort="Thuilliez, Christian" uniqKey="Thuilliez C" first="Christian" last="Thuilliez">Christian Thuilliez</name></author><author><name sortKey="Leizorovicz, Alain" sort="Leizorovicz, Alain" uniqKey="Leizorovicz A" first="Alain" last="Leizorovicz">Alain Leizorovicz</name></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7B32EA1FF5E72DB9B85F5BDD8AFFE944A8191AAB</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1093/ndt/gfm417</idno><idno type="url">https://api.istex.fr/document/7B32EA1FF5E72DB9B85F5BDD8AFFE944A8191AAB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001721</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001721</idno><idno type="wicri:Area/Istex/Curation">001721</idno><idno type="wicri:Area/Istex/Checkpoint">001295</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001295</idno><idno type="wicri:doubleKey">0931-0509:2007:Kessler M:predictors:of:cardiovascular</idno><idno type="wicri:Area/Main/Merge">009A29</idno><idno type="wicri:Area/Main/Curation">009056</idno><idno type="wicri:Area/Main/Exploration">009056</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study</title><author><name sortKey="Kessler, Michele" sort="Kessler, Michele" uniqKey="Kessler M" first="Michèle" last="Kessler">Michèle Kessler</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Grunfeld, Jean Pierre" sort="Grunfeld, Jean Pierre" uniqKey="Grunfeld J" first="Jean Pierre" last="Grünfeld">Jean Pierre Grünfeld</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Thuilliez, Christian" sort="Thuilliez, Christian" uniqKey="Thuilliez C" first="Christian" last="Thuilliez">Christian Thuilliez</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Leizorovicz, Alain" sort="Leizorovicz, Alain" uniqKey="Leizorovicz A" first="Alain" last="Leizorovicz">Alain Leizorovicz</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nephrology, University Hospital of Nancy, Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Nephrology Dialysis Transplantation</title><idno type="ISSN">0931-0509</idno><idno type="eISSN">1460-2385</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2007-12">2007-12</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="3573">3573</biblScope><biblScope unit="page" to="3579">3579</biblScope></imprint><idno type="ISSN">0931-0509</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0931-0509</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background. Cardiovascular events (CVE) are a major cause of morbidity and mortality in end-stage renal disease (ESRD) patients. These patients are often excluded from CV clinical trials, and the prognostic factors associated with CVE in patients with ESRD have not been fully explored. A risk prediction model was created from the FOSIDIAL trial to identify factors predictive of CVE and to evaluate the relative strength of known predictors when considered together in a multivariate model. Methods. FOSIDIAL was a prospective, randomized, double-blind study with 2-year follow-up and CVE adjudication. The study enrolled 397 patients with ESRD and left ventricular hypertrophy (LVH). CVE included cardiovascular death, non-fatal myocardial infarction, unstable angina, stroke, revascularization, heart failure hospitalization, resuscitated cardiac arrest and confirmed stroke. The model was built using a forward selection of all baseline variables. A structural equation model (SEM) was used to identify factors with an indirect association with CVE. Results. CV history was the most important prognostic factor, followed by C-reactive protein (CRP), left ventricular mass index, diabetes and age. Smoking, low HDL, female gender and Kt/V were indirectly associated with CVE. Conclusion. Prior CV disease, elevated CRP, LVH, diabetes or advanced age identifies patients at the highest risk for CVE. These data may be useful to detect high risk patients, to define potential targets for pharmacologic intervention, and to plan future studies in ESRD. Further research is needed to identify effective approaches that reduce the rate of CVE in these patients.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Kessler, Michele" sort="Kessler, Michele" uniqKey="Kessler M" first="Michèle" last="Kessler">Michèle Kessler</name></region><name sortKey="Grunfeld, Jean Pierre" sort="Grunfeld, Jean Pierre" uniqKey="Grunfeld J" first="Jean Pierre" last="Grünfeld">Jean Pierre Grünfeld</name><name sortKey="Kessler, Michele" sort="Kessler, Michele" uniqKey="Kessler M" first="Michèle" last="Kessler">Michèle Kessler</name><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><name sortKey="Leizorovicz, Alain" sort="Leizorovicz, Alain" uniqKey="Leizorovicz A" first="Alain" last="Leizorovicz">Alain Leizorovicz</name><name sortKey="Thuilliez, Christian" sort="Thuilliez, Christian" uniqKey="Thuilliez C" first="Christian" last="Thuilliez">Christian Thuilliez</name><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009056 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009056 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7B32EA1FF5E72DB9B85F5BDD8AFFE944A8191AAB
|texte= Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study
}}
| This area was generated with Dilib version V0.6.33. |  |